Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase

The repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) is a validated predictor of benefit from temozolomide (TMZ) in glioblastoma. However, only 10% of patients with MGMT-methylated metastatic colorectal cancer (mCRC) respond to TMZ.

Source: European Journal of Cancer - December 19, 2018 Category: Cancer & Oncology Authors: Sarit Schwartz, Chris Szeto, Yuan Tian, Fabiola Cecchi, Salvatore Corallo, Maria Alessandra Calegari, Maria Di Bartolomeo, Federica Morano, Alessandra Raimondi, Giovanni Fuc à, Antonia Martinetti, Ivana De Pascalis, Maurizio Martini, Antonino Belfiore, M Tags: Original Research Source Type: research